

# CITATION REPORT

List of articles citing

## Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study

DOI: 10.1007/s40259-018-0293-2  
BioDrugs, 2018, 32, 367-375.

**Source:** <https://exaly.com/paper-pdf/71311945/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
9	Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study. <i>Drug Safety</i> , <b>2019</b> , 42, 1437-1447	5.1	16
8	Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice. <i>Pharmacology Research and Perspectives</i> , <b>2020</b> , 8, e00594	3.1	1
7	Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. <i>BioDrugs</i> , <b>2021</b> , 35, 239-254	7.9	4
6	Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of ecuzumab. <i>Annals of Hematology</i> , <b>2021</b> , 100, 2689-2698	3	5
5	Current Status of Renal Anemia Pharmacotherapy-What Can We Offer Today. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	0
4	Anemia. <b>2021</b> ,		
3	Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trial. <i>Chronic Diseases and Translational Medicine</i> , <b>2022</b> , 8, 59-70	3.9	
2	Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018. <i>Advances in Therapy</i> ,	4.1	
1	Epoetin alfa biosimilar (HX575): A review of 15 years post-approval clinical experience. <b>2023</b> , 181, 103894		0